NEW YORK, January 1, 2026, 11:36 ET — Market closed
- Intelligent Bio Solutions (INBS) last closed at $9.53 on Dec. 31, up 132.4%, before slipping to about $8.23 in late after-hours trade.
- The company said it struck a $10.0 million private placement with two healthcare-focused institutional investors, expected to close on or about Jan. 2.
- Earlier, INBS said a new manufacturing partnership is expected to cut production costs by more than 40% and lift gross margin by about 20 percentage points ahead of planned U.S. entry in 2026.
Intelligent Bio Solutions Inc. shares swung sharply into year-end after the medical-device maker said it would raise about $10 million in a private placement, prompting a drop in after-hours trading following a session in which the stock more than doubled.
With U.S. stock markets closed on Thursday for New Year’s Day, the move left investors digesting dilution risk and execution questions before trading resumes on Friday.
The fundraise announcement came hours after Intelligent Bio Solutions said it had signed a new manufacturing partnership that it expects to lower costs and support a planned U.S. market entry in 2026, adding to the stock’s volatility.
In its financing announcement, the company said it agreed to issue 2,298,850 common shares (or pre-funded warrants in lieu thereof) plus two series of warrants to buy up to the same number of shares in each series, at a combined purchase price of $4.35 per share and associated warrants.
The warrants carry an exercise price of $4.10 per share and are exercisable immediately upon issuance, the company said, with the private placement expected to close on or about Jan. 2, subject to customary conditions. Ladenburg Thalmann & Co. Inc. is acting as exclusive placement agent, it added.
A private placement is a sale of securities to a small group of investors rather than the broader public market. Warrants are options that can increase the share count later if exercised, which investors often view as potentially dilutive.
Earlier on Wednesday, Intelligent Bio Solutions said it partnered with Syrma Johari MedTech Ltd. to scale production of its Intelligent Fingerprinting Drug Screening Reader, a fingerprint sweat-based drug test system the company says can return results in under 10 minutes.
The company said the partnership is expected to deliver annual production cost savings of more than 40% and improve gross margin — the share of revenue left after direct production costs — by about 20 percentage points versus its prior manufacturing arrangement. It also said Syrma Johari’s manufacturing capacity is roughly four times its current capacity.
“Partnering with Syrma Johari is a strategically significant milestone for our business,” Callistus Sequeira, vice president of global quality and operations, said in the statement. Intelligent Bio Solutions Inc.
INBS last closed at $9.53 on Dec. 31, up $5.43, after touching an intraday high of $12.94. Volume topped 108 million shares, far above typical activity for a microcap stock, and shares were down about 13.6% at $8.23 in late after-hours trading.
Investors will likely focus on whether the private placement and attached warrants create an overhang, particularly once resale registration is filed and the new shares become freely tradable. The company said it plans to use proceeds for working capital and general corporate purposes.
Before the next session, traders will also juggle a return from the holiday break with scheduled U.S. data, including weekly jobless claims at 8:30 a.m. and construction spending at 10:00 a.m. ET on Jan. 2, according to the New York Fed’s calendar.
Technically, investors may treat the $4.35 combined unit price and the $4.10 warrant strike as reference points, while watching whether the stock holds above its after-hours levels and below Wednesday’s $12.94 peak. The stock’s 52-week range has run from $4.03 to $27.50, underscoring the volatility risk.
Beyond the financing close, attention turns to any additional filings tied to the transaction and to the next quarterly update; MarketBeat lists INBS’s next earnings date as estimated for Feb. 12, based on prior reporting patterns.
